ERBB2 and breast cancer: HER2-enriched breast cancer and TNBC subtypes maintain the highest propensity to metastasize, and since TNBCs are difficult to treat, we next investigated whether dual-targeting of tGLI1 and GP130 can inhibit TNBC metastasis.